Keytruda looks set for use in important first-line lung cancer setting

24 May 2018

Another trial success gave shares in New Jersey, USA-based drugmaker Merck & Co (NYSE: MRK) a boost yesterday, with the firm announcing a positive result from the Phase III KEYNOTE-407 trial testing Keytruda (pembrolizumab) together with chemo in lung cancer.

The trial met the dual primary endpoints of overall survival (OS) and progression-free survival (PFS), showing that patients with metastatic squamous non-small cell lung cancer (sNSCLC) survived significantly longer.

Positive data from an interim analysis, released in March, raised hopes that the firm would succeed in broadening the marketable use for the drug, to include the key first-line lung cancer setting.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK